3-(3-甲基-哌啶-1-基)-丙胺 | 14156-91-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-(3-甲基-哌啶-1-基)-丙胺
• 中文别名: 3-(3-甲基-1-哌啶基)丙胺；3-(3-甲基哌啶-1-基)丙-1-胺；3-(2-甲基-1-哌啶基)丙胺；2-甲基-1-哌啶丙胺；3-(3-甲基-1-哌啶基)丙-1-胺
• 英文名称: (±)-3-(3-methylpiperidin-1-yl)propan-1-amine
• 英文别名: 3-methyl-1-piperidinepropanamine；3-(3-methyl-piperidin-1-yl)-propylamine；3-(3-methyl-piperidino)-propylamine；3-(3-Methyl-piperidino)-propylamin；3-(3-methyl-1-piperidinyl)-1-propanamine；3-<3-Methyl-piperidino>-propylamin；3-(3-Methylpiperidin-1-yl)propan-1-amine
• CAS: 14156-91-3
• 化学式: C₉H₂₀N₂
• mdl: MFCD03445120
• 分子量: 156.271
• InChiKey: ADIQUBKLXXCKLT-UHFFFAOYSA-N

物化性质

• 熔点：
  99-102 °C
• 沸点：
  110-112 °C(Press: 27 Torr)
• 密度：
  0.891±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-(3-甲基-哌啶-1-基)-丙胺 、 α-甲基肉桂醛 在 sodium tetrahydroborate 作用下， 以 二氯甲烷 、 甲醇 为溶剂， 反应 18.25h， 生成 (2-methyl-3-phenyl-allyl)-[3-(3-methyl-piperidin-1-yl)-propyl]-amine
  参考文献：
  名称：

  [EN] INHIBITORS OF THE BINDING OF CHEMOKINES I-TAC OR SDF-1 TO THE CCXCKR2 RECEPTOR
  [FR] INHIBITEURS DE CCXCKR2 D'EXPRESSION TUMORALE HUMAINE

  摘要：

  公开号：

  WO2004058705A3
• 作为产物：
  描述：

  3-(3-methyl-piperidino)-propionitrile 在 镍 氨 、 氢气 作用下， 以 甲醇 为溶剂， 生成 3-(3-甲基-哌啶-1-基)-丙胺
  参考文献：
  名称：

  [EN] INHIBITORS OF THE BINDING OF CHEMOKINES I-TAC OR SDF-1 TO THE CCXCKR2 RECEPTOR
  [FR] INHIBITEURS DE CCXCKR2 D'EXPRESSION TUMORALE HUMAINE

  摘要：

  公开号：

  WO2004058705A3

文献信息

• Sulfonamides having antiangiogenic and anticancer activity
  申请人：——

  公开号：US20040157836A1

  公开（公告）日：2004-08-12

  Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.

  描述了具有蛋氨酸氨基肽酶-2抑制剂（MetAP2）的化合物。还描述了包括这些化合物的药物组合物、使用这些化合物的治疗方法、抑制血管生成的方法以及治疗癌症的方法。
• (5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones. A series of novel potential antipsychotic agents
  作者：Lawrence D. Wise、Donald E. Butler、Horace A. DeWald、David Lustgarten、Linda L. Coughenour、David A. Downs、Thomas G. Heffner、Thomas A. Pugsley

  DOI：10.1021/jm00159a011

  日期：1986.9

  (5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanone (1) was found to have an antipsychotic-like profile in behavioral tests predictive of antipsychotic efficacy but, unlike available antipsychotic agents, did not bind in vitro to dopamine receptors. Upon further evaluation, 1 was found to cause clonic seizures in aged rodents. An examination of related structures revealed that 5-(substituted aminoacetamide) analogues of 1 shared this novel pharmacology and did not cause seizures. The synthesis and pharmacological evaluation of this series of compounds are described. Two compounds, 2-(diethylamino)acetamide (25) and 2-[[3-(2-methyl-1-piperidinyl)propyl]-amino]acetamide (38), were selected for examination in secondary tests. Like known antipsychotics both compounds reduced spontaneous locomotion in mice at doses that did not cause ataxia and inhibited conditioned avoidance selectively in both rats and monkeys. Unlike known antipsychotics neither 25 nor 38 elicited dystonic movements in haloperidol-sensitized cebus monkeys, a primate model of antipsychotic-induced extrapyramidal side effects. Biochemical studies indicated that these compounds act via a nondopaminergic mechanism. Neither 25 nor 38 bound to dopamine receptors in vitro or caused changes in striatal dopamine metabolism in vivo. In addition, they did not raise serum prolactin levels as do known antipsychotics. Although adverse animal toxicological findings have precluded clinical evaluation of these agents, the present results indicate that it is possible to identify at the preclinical level nondopaminergic compounds with antipsychotic-like properties.

  (5-氨基-1,3-二甲基-1H-吡唑-4-基)(2-氟苯基)甲酮(1)在预测抗精神病药物效力的行为测试中被发现具有抗精神病样特性,但它与现有的抗精神病药物不同,体外不与多巴胺受体结合。在进一步的评估中,发现1会导致老年啮齿类动物出现阵挛性癫痫。对相关结构的分析表明,1的5-(取代氨基乙酰胺)类似物具有这种新颖的药理学特性,但不会引起癫痫。文中描述了这一系列化合物的合成和药理学评价。两种化合物,2-(二乙基氨基)乙酰胺(25)和2-[[3-(2-甲基-1-吡咯烷基)丙基]氨基]乙酰胺(38),被选中进行次级测试。与已知的抗精神病药物一样,这两种化合物在不引起共济失调的情况下,降低了小鼠的自发运动,并在大鼠和猴子中选择性抑制了条件回避反应。与已知的抗精神病药物不同,25和38都不会引起氯丙嗪敏感的卷尾猴的迟发性运动障碍,这是一种模拟抗精神病药物引起的锥体外系副作用的灵长类动物模型。生化研究表明,这些化合物通过非多巴胺能机制发挥作用。25和38在体外均不与多巴胺受体结合,也不会改变纹状体中多巴胺的代谢,并且与已知的抗精神病药物不同,它们不会升高血清催乳素水平。尽管不良的动物毒理学结果排除了这些药物的临床评估,但目前的结果表明,在临床前阶段有可能发现具有抗精神病样特性的非多巴胺能化合物。
• Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same
  申请人：Fahey Robert C.

  公开号：US20100022509A1

  公开（公告）日：2010-01-28

  The present invention utilizes three families of bacterial enzymes, which play a key role in mycothiol biosynthesis. The three families are bacterial cysteine:glucosaminyl inositol ligases (MshC) with catalytic ligase activity for ligation of glucosaminyl inositol and cysteine, bacterial acetyl-CoA:Cys-GlcN-Ins acetyltransferases (MshD) with catalytic activity for addition of an acetyl group to Cys-GlcN-Ins and bacterial MshA glycosyltransferase with catalytic activity for production of GlcNAc-Ins. The invention provides methods for using the mycothiol biosynthesis ligases, acetyltransferases or glycosyltransferases in drug screening assays to determine compounds that inhibit activity. The invention also provides inhibitors of the production or activity of the enzymes of mycothiol biosynthesis, and use of the inhibitors for treating microbial infection.

  本发明利用三种细菌酶家族，它们在肌硫醇生物合成中起着关键作用。这三个家族是：具有催化配体活性的细菌半胱氨酸：葡萄糖胺酰肌醇连接酶（MshC），用于连接葡萄糖胺酰肌醇和半胱氨酸；具有催化活性的细菌乙酰辅酶A：半胱氨酸-GlcN-Ins乙酰转移酶（MshD），用于向Cys-GlcN-Ins添加乙酰基；以及具有催化活性的细菌MshA糖基转移酶，用于生产GlcNAc-Ins。本发明提供了使用肌硫醇生物合成连接酶、乙酰转移酶或糖基转移酶进行药物筛选测定的方法，以确定抑制活性的化合物。本发明还提供了肌硫醇生物合成酶的产生或活性的抑制剂，并将其用于治疗微生物感染。
• INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2
  申请人：Melikian Anita

  公开号：US20100144720A1

  公开（公告）日：2010-06-10

  Pharmaceutical compositions containing organic compounds or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.

  本发明涉及含有有机化合物或其盐的制药组合物，其作为SDF-1或I-TAC趋化因子的调节剂。这些化合物和组合物在癌症治疗中特别是在抑制癌症增殖、生长和转移方面具有用途。本发明还揭示了干扰SDF-1和/或I-TAC与CCXCKR2受体结合以及使用本发明的化合物和制药组合物治疗癌症的方法。
• Basic acyl amides of (5-amino-1,3-dialkylpyrazol-4-yl)(aryl)methanones, processes for their production, and pharmaceutical compositions containing such compounds
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0068806A2

  公开（公告）日：1983-01-05

  Basic acylamides of (5-amino-1,3-dialkylpyrazol-4-yl)-(aryl)methanones and their pharmaceutically acceptable salts are provided, which have the formula: where the radicals are as defined in the specification. These compounds are useful for treating psychoses. Also provided are processes for preparing the compounds of the invention, and pharmaceutical compositions containing these compounds.

  本发明提供了(5-氨基-1,3-二烷基吡唑-4-基)-(芳基)甲酮的碱性酰酰胺及其药学上可接受的盐，其式为： 其中基团如说明书中所定义。 这些化合物可用于治疗精神病。 还提供了制备本发明化合物的工艺和含有这些化合物的药物组合物。